(Q34508460)

2 August 2017

1 reference

title

Structural development of biological response modifiers based on thalidomide (English)

1 reference

2 August 2017

0 references

Yuichi Hashimoto

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

Bioorganic & Medicinal Chemistry

2 August 2017

published in

1 reference

2 August 2017

volume

10

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

461-479

1 reference

Retinobenzoic acids and nuclear retinoic acid receptors.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Novel small molecule nonpeptide aminopeptidase n inhibitors with a cyclic imide skeleton.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Thalidomide has 37-year history

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Thalidomide update: regulatory aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Thalidomide increases both REM and stage 3-4 sleep in human adults: a preliminary study.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

THALIDOMIDE AND CONGENITAL ABNORMALITIES

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

A short history of thalidomide embryopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Thalidomide--a revival story

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Thalidomide and its dermatologic uses

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Thalidomide in cancer: potential uses and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

1 reference

7 January 2021

Thalidomide in the treatment of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Current role of thalidomide in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Potential novel uses of thalidomide: focus on palliative care

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Thalidomide: current and potential clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Thalidomide as an anti-angiogenic agent in relapsed gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Tumor necrosis factors in 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Thalidomide inhibits the replication of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Enhancement of phorbol ester-induced production of tumor necrosis factor alpha by thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

N-Alkylphthalimides: structural requirement of thalidomidal action on 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor alpha production by human leukemia HL-60 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Modulators of tumor necrosis factor alpha production bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Tumor necrosis factor-alpha production-inhibiting activity of phthalimide analogues on human leukemia THP-1 cells and a structure-activity relationship study

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Phenylphthalimides with tumor necrosis factor alpha production-enhancing activity

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Benzylphthalimides and phenethylphthalimides with thalidomide-like activity on the production of tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Tumor necrosis factor alpha production enhancers with a phenylphthalimide skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Enhancement of phorbol ester-induced production of tumor necrosis factor-alpha by 2,6-dimethylphenylphthalimide

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Enhancement of 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor alpha production by phenethylphthalimide analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Enhanced potency of perfluorinated thalidomide derivatives for inhibition of LPS-induced tumor necrosis factor-alpha production is associated with a change of mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Tumor necrosis factor-alpha production enhancing activity of substituted 3'-methylthalidomide: influence of substituents at the phthaloyl moiety on the activity and stereoselectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Inducer-specific regulators of tumor necrosis factor alpha production

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Toxicity and Teratogenicity of Optical Isomers of Thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

(S)-form of alpha-methyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Augmentation by phthalimides of phorbol ester-induced expression of tumor necrosis factor alpha message

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Thymidine phosphorylase is angiogenic and promotes tumor growth.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Thymidine phosphorylase inhibitors with a homophthalimide skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Fgf10 is essential for limb and lung formation

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Retinobenzoic acids. 3. Structure-activity relationships of retinoidal azobenzene-4-carboxylic acids and stilbene-4-carboxylic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Differentiation inducers of human promyelocytic leukemia cells HL-60. Azobenzenecarboxylic acids and stilbenecarboxylic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Differentiation inducers of human promyelocytic leukemia cells HL-60. Phenylcarbamoylbenzoic acids and polyene amides

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Anti-androgenic activity of substituted azo- and azoxy-benzene derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

New type inducers of differentiation of human HL-60 promyelocytic leukemia cells. Terephthalic anilides

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Proline-dependent structural and biological properties of peptides and proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Specific inhibitor of puromycin-sensitive aminopeptidase with a homophthalimide skeleton: identification of the target molecule and a structure-activity relationship study

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Potent homophthalimide-type inhibitors of B16F10/L5 mouse melanoma cell invasion

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Aminosugar derivatives as potential anti-human immunodeficiency virus agents

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Novel alpha-glucosidase inhibitors with a tetrachlorophthalimide skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Alpha-glucosidase inhibitors with a phthalimide skeleton: structure-activity relationship study

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Alpha-glucosidase inhibitors with a 4,5,6,7-tetrachlorophthalimide skeleton pendanted with a cycloalkyl or dicarba-closo-dodecaborane group.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Determination of the photoaffinity-labeled site on the ligand-binding domain of retinoic acid receptor alpha.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Identification of the fragment photoaffinity-labeled with azidodansyl-rhizoxin as Met-363-Lys-379 on beta-tubulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900308-X

7 January 2021

10.1016/S0968-0896(01)00308-X

Identifiers

DOI

1 reference

2 August 2017

1 reference